View Expired Tender

Get immediate access to tenders like the one below by subscribing now to Tenders Direct. We will set up your personalised profile and send you tender alerts direct to your mailbox as soon as they are published. You will also benefit from having access to historical tenders.

Notice Summary

Title:
United Kingdom-Runcorn: NHS Framework for the NHS North of England Region, Branded Medicines
Document Ref:
468163-2019
Document Type:
Contract Notice - Open Procedure
Published By:
The NHS Commissioning Board (operating Under the name of NHS England)
Date Published:
07 October 2019
Deadline Date:
07 November 2019
Document Source:
Framework/DPS:
Yes
Alert Profile:
Labels:

Notice Abstract

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and other Monoclonal Antibodies, and Fondaparinux.Offer reference number: CM/PHR/16/5527CM/PHR/16/5527/01 — Tranche B: 1.3.2020 to 28.2.2022 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.CM/PHR/16/5527/02 – Annual tranche — cytokine modulators and other monoclonal antibodies — 1.3.2020 to 28.2.2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1.3.2020 – 31.8.2021, South of England – 1.3.2020 – 31.8.2020, Midlands and East – 1.3.2020 – 28.2.2021, all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.

Notice Details

Contract notice

Directive 2014/24/EU - Public Sector Directive

Directive 2014/24/EU

Section I: Contracting Change entity

I.1) Name and addresses

The NHS Commissioning Board (operating Under the name of NHS England)

2nd Floor, Rutland House

Runcorn

WA7 2ES

UK

E-mail: michelle.clarke6@nhs.net

NUTS: UK

Internet address(es)

Main address: https://nhsengland.bravosolutio.co.uk

I.2) Joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge at:

https://nhsenland.bravosolution.co.uk


Additional information can be obtained from the abovementioned address


Tenders or requests to participate must be sent electronically to:

https://nhsenland.bravosolution.co.uk


Tenders or requests to participate must be sent to the abovementioned address


Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at:

https://nhsenland.bravosolution.co.uk


I.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and other Monoclonal Antibodies, and Fondaparinux

Reference number: CM/PHR/16/5527

II.1.2) Main CPV code

33600000

 

II.1.3) Type of contract

Supplies

II.1.4) Short description

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and other Monoclonal Antibodies, and Fondaparinux.

Offer reference number: CM/PHR/16/5527

CM/PHR/16/5527/01 — Tranche B: 1.3.2020 to 28.2.2022 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.

CM/PHR/16/5527/02 – Annual tranche — cytokine modulators and other monoclonal antibodies — 1.3.2020 to 28.2.2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.

CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1.3.2020 – 31.8.2021, South of England – 1.3.2020 – 31.8.2020, Midlands and East – 1.3.2020 – 28.2.2021, all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.

II.1.5) Estimated total value

Value excluding VAT: 987 906 001.00 GBP

II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

II.2) Description

Lot No: 1

II.2.1) Title

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKC

UKD

UKE

Main site or place of performance:

Please refer to document 03 schedule 8 in the ITO documents for the full list of purchasing points.

II.2.4) Description of the procurement

CM/PHR/16/5527/01 — 1.3.2020 to 28.2.2022 – NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/03/2020

End: 28/02/2022

This contract is subject to renewal: No

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: Yes

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 2

II.2.1) Title

NHS Framework for the NHS North of England Region, Branded Medicines – Annual Tranche — Cytokine Modulators and other Monoclonal Antibodies

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKC

UKD

UKE

Main site or place of performance:

Please refer to document 3 schedule 8 in the ITO pack for full list of purchasing points.

II.2.4) Description of the procurement

CM/PHR/16/5527/02 – 1.3.2020 to 28.2.2021 — NHS Framework for the NHS North of England Region, Branded Medicines – Annual Tranche — cytokine modulators and other monoclonal antibodies with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/03/2020

End: 28/02/2021

This contract is subject to renewal: No

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: Yes

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 3

II.2.1) Title

NHS Framework Agreement for Fondaparinux

II.2.2) Additional CPV code(s)

33600000

II.2.3) Place of performance

NUTS code:

UKC

UKD

UKE

UKF

UKG

UKH

UKI

UKJ

UKK

Main site or place of performance:

Please refer to document 3 schedule 8 in the ITO documents for a full list of purchasing points.

II.2.4) Description of the procurement

CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1.3.2020 – 31.8.2021, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.

South of England – 1.3.2020 – 31.8.2020, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.

Midlands and East – 1.3.2020 – 28.2.2021, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/03/2020

End: 21/08/2021

This contract is subject to renewal: No

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: Yes

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section III: Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.2) Economic and financial standing

List and brief description of selection criteria:

Please refer to the award criteria contained in the invitation to offer.

III.1.3) Technical and professional ability

List and brief description of selection criteria:

Please refer to the award criteria contained in the invitation to offer.

III.2) Conditions related to the contract

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement with several operators.

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date: 07/11/2019

Local time: 13:00

IV.2.4) Languages in which tenders or requests to participate may be submitted

EN

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 3 (from the date stated for receipt of tender)

IV.2.7) Conditions for opening of tenders

Date: 07/11/2019

Local time: 13:00

Place:

Runcorn

Information about authorised persons and opening procedure:

Commercial Medicines Unit Employee.

Section VI: Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.3) Additional information

Responding to this notice. Any supplier may be disqualified who does not respond to the following in the requisite manner:

1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at: http://www.nhsengland.bravosolution.co.uk

Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested), through the eTendering portal as follows:

1.1) If not already registered, candidates should register on the eTendering portal at: https://www.nhsengland.bravosolution.co.uk and click the link to register:

— accept the terms and conditions and click continue,

— enter your correct business and user details,

— note the username you chose and click Save when complete,

— you will shortly receive an email with your unique password (please keep this secure).

1.2) Once registered, candidates must express interest as follows:

(a) login to the eTendering portal;

(b) select response to ITT;

(c) select ITTs Open To All Suppliers;

(d) access listing related to this procurement.

For NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and other monoclonal antibodies, and fondaparinux and view details;

(e) click on express interest button at the top of the page;

(f) once you have expressed interest, the ITT will move to My ITTs, where you can download additional documentation (if required), and construct your reply as instructed. You must then publish your reply using the Publish button.

1.3) For any support in registering on the portal or submitting your expression of interest please contact the eTendering Help-desk at +44 800 368 4850 or: help@bravosolution.co.uk

2) General supplier information. To manage and assess supplier information the contracting authority requests candidates provide their company profile in the Governments supplier information database, sid4gov, as follows:

2.1) If not already registered, candidates must go to the following web page: https://sid4gov.cabinetoffice.gov.uk/ and select Register for sid4gov at the bottom of the page. Key in details as requested to search for your company. If you do not have a D-UNS ® Number, click on the link at the right of the page to obtain a number from D&B. Candidates must obtain a Dun and Bradstreet (D&B) D-U-N-S® Number to enable registration on sid4gov.

2.2) Once registration is complete you are able to create and update your sid4gov company profile. Candidates should ensure all the mandatory fields of their sid4gov profile are completed and up to date for each procurement exercise. D&B data will be supplied automatically by D&B;

2.3) For further help or information concerning sid4gov, please contact the sid4gov Helpdesk at: support@nqc.com or telephone +44 (0) 845 299 2994.

The framework agreement is for the benefit of other participating NHS bodies (whether acting individually,or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

Variants: an offerer is permitted to submit any number of variants to the Authority (subject to the minimum requirements set out in the ITO Terms of Offer Document 2, paragraph 8.2.1.

VI.4) Procedures for review

VI.4.1) Review body

The Royal Courts of Justice

London or any of the district registry of the High Court

UK

VI.5) Date of dispatch of this notice

03/10/2019

Current Notes